Publication | Closed Access

Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer

Androgen ReceptorUrologyMedicineHormonal ReceptorPharmacologyCombination TreatmentPharmacotherapyCastration-resistant Prostate CancerAnti-cancer AgentProstatic DiseaseOncologyEndocrine-related Cancer